Cited 3 times in
Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유철주 | - |
dc.contributor.author | 한승민 | - |
dc.contributor.author | 한정우 | - |
dc.date.accessioned | 2022-02-23T01:28:35Z | - |
dc.date.available | 2022-02-23T01:28:35Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187720 | - |
dc.description.abstract | Purpose: Effectiveness and safety of clofarabine (one of the treatment mainstays in pediatric patients with relapsed/refractory acute lymphoblastic leukemia [ALL]) was assessed in Korean pediatric patients with ALL to facilitate conditional coverage with evidence development. Materials and methods: In this multicenter, prospective, observational study, patients receiving clofarabine as mono/combination therapy were followed up every 4-6 weeks for 6 months or until hematopoietic stem cell transplantation (HSCT). Response rates, survival outcomes, and adverse events were assessed. Results: Sixty patients (2-26 years old; 65% B-cell ALL, received prior ≥ 2 regimen, 68.3% refractory to previous regimen) were enrolled and treated with at least one dose of clofarabine; of whom 26 (43.3%) completed 6 months of follow-up after the last dose of clofarabine. Fifty-eight patients (96.7%) received clofarabine combination therapy. Overall remission rate (complete remission [CR] or CR without platelet recovery [CRp]) was 45.0% (27/60; 95% confidence interval [CI], 32.4 to 57.6) and the overall response rate (CR, CRp, or partial remission [PR]) was 46.7% (28/60; 95% CI, 34.0 to 59.3), with 11 (18.3%), 16 (26.7%), and one (1.7%) patients achieving CR, CRp, and PR, respectively. The median time to remission was 5.1 weeks (95% CI, 4.7 to 6.1). Median duration of remission was 16.6 weeks (range, 2.0 to 167.6 weeks). Sixteen patients (26.7%) proceeded to HSCT. There were 24 deaths; 14 due to treatment-emergent adverse events. Conclusion: Remission with clofarabine was observed in approximately half of the study patients who had overall expected safety profile; however, there was no favorable long-term survival outcome in this study. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antimetabolites, Antineoplastic / therapeutic use | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Clofarabine / therapeutic use* | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Drug Resistance, Neoplasm* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Hematopoietic Stem Cell Transplantation / mortality* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Neoplasm Recurrence, Local / pathology | - |
dc.subject.MESH | Neoplasm Recurrence, Local / therapy* | - |
dc.subject.MESH | Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology | - |
dc.subject.MESH | Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology | - |
dc.subject.MESH | Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy* | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Salvage Therapy* | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Young Adult | - |
dc.title | Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학교실) | - |
dc.contributor.googleauthor | Jung Yoon Choi | - |
dc.contributor.googleauthor | Che Ry Hong | - |
dc.contributor.googleauthor | Kyung Taek Hong | - |
dc.contributor.googleauthor | Hyoung Jin Kang | - |
dc.contributor.googleauthor | Seongkoo Kim | - |
dc.contributor.googleauthor | Jae Wook Lee | - |
dc.contributor.googleauthor | Pil Sang Jang | - |
dc.contributor.googleauthor | Nack-Gyun Chung | - |
dc.contributor.googleauthor | Bin Cho | - |
dc.contributor.googleauthor | Hyery Kim | - |
dc.contributor.googleauthor | Kyung-Nam Koh | - |
dc.contributor.googleauthor | Ho Joon Im | - |
dc.contributor.googleauthor | Jong Jin Seo | - |
dc.contributor.googleauthor | Seung Min Hahn | - |
dc.contributor.googleauthor | Jung Woo Han | - |
dc.contributor.googleauthor | Chuhl Joo Lyu | - |
dc.contributor.googleauthor | Eu Jeen Yang | - |
dc.contributor.googleauthor | Young Tak Lim | - |
dc.contributor.googleauthor | Keon Hee Yoo | - |
dc.contributor.googleauthor | Hong Hoe Koo | - |
dc.contributor.googleauthor | Hoon Kook | - |
dc.contributor.googleauthor | In Sang Jeon | - |
dc.contributor.googleauthor | Hana Cho | - |
dc.contributor.googleauthor | Hee Young Shin | - |
dc.identifier.doi | 10.4143/crt.2020.289 | - |
dc.contributor.localId | A02524 | - |
dc.contributor.localId | A04299 | - |
dc.contributor.localId | A04325 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 33421973 | - |
dc.subject.keyword | Acute lymphoblastic leukemia | - |
dc.subject.keyword | Clofarabine | - |
dc.subject.keyword | Leukemia | - |
dc.subject.keyword | Pediatric cancer | - |
dc.subject.keyword | Pediatric malignancy | - |
dc.contributor.alternativeName | Lyu, Chuhl Joo | - |
dc.contributor.affiliatedAuthor | 유철주 | - |
dc.contributor.affiliatedAuthor | 한승민 | - |
dc.contributor.affiliatedAuthor | 한정우 | - |
dc.citation.volume | 53 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1184 | - |
dc.citation.endPage | 1194 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.53(4) : 1184-1194, 2021-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.